Pharmaceutical Pipeline

Research And Development Initiatives

A cascade of inflammatory events has shown to be correlative to a number of diseases. Imagenetix is focused on developing therapies which prevent inflammatory cell infiltration and effectively treats chronic inflammatory related diseases.

Imagenetix’s first therapeutic drug is 1-TDC, for the treatment and prevention of periodontal disease. Studies conducted at Boston University have shown 1-TDC  to stop the progression of gum and bone damage and recent data suggests the reformation of gum and bone lost due to the disease. Imagenetix has initiated an active program using FDA consultants and an international clinical research organization for the submission of 1-TDC as a drug candidate.

Publications

May 2007

Hasturk H, Jones VL, Andry C, Kantarci A. 1-Tetradecanol complex reduces progression of Porphyromonas gingivalis-induced experimental periodontitis in rabbits. J. Periodontol. 2007 May;78(5):924-32.

2006

Hasturk H, Kantarci A, Jones VL, Van Dyke TE. Cetylated fatty acids in the prevention of periodontal inflammation. J Dent Res 85(Spec Iss B): Abstract #83342

Presentations

2006

Hasturk H, Kantarci A, Jones VL, Van Dyke TE. Cetylated fatty acids in the prevention of periodontal inflammation. International Association for Dental Research General Session. June 28-July 1, 2006, Brisbane, Australia.